Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures

Drug Name

Afinitor Disperz®/everolimus

Developed by

Novartis

Therapy Class

Pharmacologic therapy

Current Indication

Tuberous sclerosis complex (TSC)-associated partial-onset seizures

Market Sector

Genetics

Development Status

Approved in the US and Europe
Expand

Go Top